Bio-Techne (NASDAQ: TECH) reported Q2 EPS of $0.81, $0.04 worse than the analyst estimate of $0.85. Revenue for the quarter came in at $131.8 million versus the consensus estimate of $134.5 million.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.